As the regulatory factor for cell growth first discovered, the nerve growth factor (NGF) features dual biological functions of nourishing neurons and promoting neurite growth, and plays an important role in regulating the development, differentiation, growth, regeneration and functional property expression of central and surrounding neurons.
Italian scientist Montalcini and U.S. scientist Cohen won the 86th Nobel Prize in Physiology or Medicine in 1986 due to the discovery of NGF and outstanding contributions to NGF research; the experiments of the two scientists showed that NGF could promote the cranial nerve regeneration, which caused a great sensation in the medical community.
NGF can be extracted from mice, snake venom and human placentas, etc. The NGF extracted from mouse submandibular gland is called mouse nerve growth factor (mNGF) and that from human placentas is called human nerve growth factor (hNGF). hNGF is currently not available in the market, and mNGF is the main NGF in the market owing to the richness, high homology with humans (reaching 90%) and simple extraction process.
China is at the forefront of the world in researching NGF. CFDA formally approved the trial production of the Nobex (mouse nerve growth factor for injection) of Xiamen Bioway (now, Sinobioway Biomedicine) on January 6, 2003, with the approval No.: GYS ZI S20020116, which is the first NGF product marketed in the world.
There have been 4 manufacturers producing "mouse nerve growth factor for injection" in China so far, separately being Nobex of Sinobioway Biomedicine, Sutaisheng of Staidson, Jinlujie of Wuhan Hiteck, and Likangle of Livzon. mNGF is mainly indicated for promoting recovery of nerve injury, and treating optic nerve injury and n-hexane induced peripheral neuropathy. mNGF is widely applied clinically as a kind of neurotrophic drug, and is frequently used by many medical departments like ophthalmology, neurology, neurosurgery and orthopedics.
Manufacturers and marketing time of mouse nerve growth factor for injection
|
Trade name |
Manufacturer |
First marketing time |
Indications on the package insert |
|
Sutaisheng |
Staidson |
April 11, 2006 |
Promoting recovery of nerve injury, and treating optic nerve injury |
|
Nobex |
Sinobioway Biomedicine |
January 6, 2003 (GYS ZI) June 12, 2006 (GYZ ZI) |
Treating n-hexane induced peripheral neuropathy, and functioning by promoting recovery of nerve injury |
|
Jinlujie |
Wuhan Hiteck Biological |
June 8, 2006 |
Treating n-hexane induced peripheral neuropathy, and functioning by promoting recovery of nerve injury |
|
Likangle |
Livzon |
May 7, 2010 |
Promoting recovery of nerve injury, and treating optic nerve injury |
According to the data disclosed in the company annual reports, the 2016 sales of the 3 mNGFs: Sutaisheng, Nobex, and Likangle totaled RMB 2.53 billion, with the marke...
(All Rights Reserved)